CD33 and neoplasm: We further demonstrated that the percentage of CD33+CD11b+HLA-DR− peripheral MDSCs was increased in CC patients compared with healthy donors, as was the percentage of tumour-derived CD33+CD11b+HLA-DR− MDSCs compared with that of tumour-adjacent tissues (Fig. 1e, f, n = 3).